

## RPS6KA3 Antibody

|                |  |
|----------------|--|
| Catalog_no :   | AB0703   |
| Applications : | WB, IHC-P  |
| Reactivity :   | H  |
| Category :     | 抗原抗体   |
| Size :         | 100 $\mu$ L/50 $\mu$ L   |
| Immunogen :    | HUMAN  |
| Specificity :  | Purified His-tagged RPS6KA3 protein(Fragment) was used to produced this monoclonal antibody.   |
| Dilution :     | WB,1:100~500;  |
| Purification : | Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.  |
| Other_name :   | Ribosomal protein S6 kinase alpha-3, S6K-alpha-3, 90 kDa ribosomal protein S6 kinase 3, p90-RSK 3, p90RSK3, Insulin-stimulated protein kinase 1, ISPK-1, MAP kinase-activated protein kinase 1b, MAPK-activated protein kinase 1b, MAPKAP kinase 1b, MAPKAPK-1b, Ribosomal S6 kinase 2, RSK-2, pp90RSK2, RPS6KA3, ISPK1, MAPKAPK1B, RSK2   |
| Isotype :      | IgG1   |
| Background :   | This gene encodes a member of the RSK (ribosomal S6 kinase) family of serine/threonine kinases. This kinase contains 2 non-identical kinase catalytic domains and phosphorylates various substrates, including members of the mitogen-activated kinase (MAPK) signalling pathway. The activity of this protein has been implicated in controlling cell growth and differentiation. Mutations in this gene have been associated with Coffin-Lowry syndrome (CLS). |
| reference :    | Peng, C., et al. FASEB J. 24(9):3490-3499(2010) Vigneron, S., et al. Oncogene 29(24):3566-3574(2010) Kang, S., et al. J. Clin. Invest. 120(4):1165-1177(2010) Yerges, L.M., et al. J. Bone Miner. Res. 24(12):2039-2049(2009) Doehn, U., et al. Mol. Cell  |